213 related articles for article (PubMed ID: 20542845)
1. A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals.
Kühne FC; Chancellor J; Mollon P; Myers DE; Louie M; Powderly WG
HIV Clin Trials; 2010; 11(2):80-99. PubMed ID: 20542845
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals in Mexico.
Contreras-Hernandez I; Becker D; Chancellor J; Kühne F; Mould-Quevedo J; Vega G; Marfatia S
Value Health; 2010 Dec; 13(8):903-14. PubMed ID: 21091827
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
[TBL] [Abstract][Full Text] [Related]
4. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
Ndegwa S
Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
[TBL] [Abstract][Full Text] [Related]
5. Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
[TBL] [Abstract][Full Text] [Related]
6. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
[TBL] [Abstract][Full Text] [Related]
7. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
Perry CM
Drugs; 2010 Jun; 70(9):1189-213. PubMed ID: 20518583
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
Furtado J; Madruga JV; Bicudo EL; da Eira M; Lopes MI; Netto EM; Santini-Oliveira M; Leite OH; Machado AA; Tupinambas U; de Andrade Neto JL; Lima MP; Pedro Rde J; Miranda AF; Lewi DS; Santos BR; Portsmouth S; Wajsbrot DB; Cassoli LM
AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1203-10. PubMed ID: 23731330
[TBL] [Abstract][Full Text] [Related]
9. Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc plus optimized background therapy in the MOTIVATE 1 and 2 trials.
Nelson M; Fisher M; Gonzalez-Garcia J; Rockstroh JK; Weinstein D; Valdez H; Mayer H; van der Ryst E; Goodrich JM; Dang N
HIV Clin Trials; 2010; 11(3):145-55. PubMed ID: 20736151
[TBL] [Abstract][Full Text] [Related]
10. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
Fätkenheuer G; Nelson M; Lazzarin A; Konourina I; Hoepelman AI; Lampiris H; Hirschel B; Tebas P; Raffi F; Trottier B; Bellos N; Saag M; Cooper DA; Westby M; Tawadrous M; Sullivan JF; Ridgway C; Dunne MW; Felstead S; Mayer H; van der Ryst E;
N Engl J Med; 2008 Oct; 359(14):1442-55. PubMed ID: 18832245
[TBL] [Abstract][Full Text] [Related]
11. The maraviroc expanded access program - safety and efficacy data from an open-label study.
Lazzarin A; Reynes J; Molina JM; Valluri S; Mukwaya G; Heera J; Craig C; van der Ryst E; Sierra-Madero JG
HIV Clin Trials; 2015; 16(1):10-21. PubMed ID: 25777185
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.
Soulie C; Peytavin G; Charpentier C; Lambert-Niclot S; Sayon S; Visseaux B; Simon A; Katlama C; Yazdanpanah Y; Descamps D; Calvez V; Marcelin AG
AIDS Res Hum Retroviruses; 2015 May; 31(5):475-8. PubMed ID: 25420695
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain.
Chaudhary MA; Moreno S; Kumar RN; Nocea G; Elbasha E
AIDS Res Hum Retroviruses; 2009 Jul; 25(7):679-89. PubMed ID: 19552590
[TBL] [Abstract][Full Text] [Related]
14. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
Hardy WD; Gulick RM; Mayer H; Fätkenheuer G; Nelson M; Heera J; Rajicic N; Goodrich J
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):558-64. PubMed ID: 20703158
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland.
Elbasha EE; Szucs T; Chaudhary MA; Kumar RN; Roediger A; Cook JR; Opravil M
HIV Clin Trials; 2009; 10(4):233-53. PubMed ID: 19723611
[TBL] [Abstract][Full Text] [Related]
16. Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.
Rossetti B; Bianco C; Bellazzi LI; Bruzzone B; Colao G; Corsi P; Monno L; Pagano G; Paolucci S; Punzi G; Setti M; Zazzi M; De Luca A
AIDS Res Hum Retroviruses; 2014 Jan; 30(1):17-24. PubMed ID: 23971941
[TBL] [Abstract][Full Text] [Related]
17. Maraviroc: a review of its use in HIV infection and beyond.
Woollard SM; Kanmogne GD
Drug Des Devel Ther; 2015; 9():5447-68. PubMed ID: 26491256
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
Bon I; Clò A; Borderi M; Colangeli V; Calza L; Morini S; Miserocchi A; Cricca M; Gibellini D; Re MC
Int J Infect Dis; 2013 Oct; 17(10):e875-82. PubMed ID: 23597487
[TBL] [Abstract][Full Text] [Related]
19. Maraviroc.
Fadel H; Temesgen Z
Drugs Today (Barc); 2007 Nov; 43(11):749-58. PubMed ID: 18174962
[TBL] [Abstract][Full Text] [Related]
20. Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.
Reuter S; Braken P; Jensen B; Sierra-Aragon S; Oette M; Balduin M; Kaiser R; Häussinger D
Eur J Med Res; 2010 Jun; 15(6):231-7. PubMed ID: 20696631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]